Lingqiang Zhang

Researcher Zhang Lingqiang, Doctoral Supervisor, Director of the Main Facility at the National Center for Protein Sciences (Beijing), Executive Deputy Director of the National Key Laboratory of Medical Proteomics, recipient of the National Science Fund for Distinguished Young Scholars, recipient of the Tan Jiazhen Life Science Innovation Award and Shulan Medicine Young Award, selected for the National Ten Thousand Talents Program Leading Talents and the National Millions of Talents Project. The main research direction is protein ubiquitination modification and the pathogenesis and treatment of diseases. The research team comprehensively uses next-generation omics (proteomics, modification omics, transcriptomics, etc.) technologies to reveal the specific activation mechanism of the Smurf1 family ubiquitin ligase, discovered the dual enzymatic function of the Smurf1 family modification ubiquitination and SUMOylation, identified Smurf1 and its co-activator CKIP-1 as potential disease treatment targets, developed interfering small nucleic acids targeting CKIP-1 and PROTAC degraders targeting Smurf1, proposed new strategies for bone formation-promoting treatment of osteoporosis and anti-modification treatment of KRAS mutation refractory colorectal cancer; analyzed the new functions and mechanisms of members of the OTU family deubiquitinase series, providing new insights for understanding the mechanisms of angiogenesis and tumor progression; revealed that ubiquitination degradation and SUMOylation inactivation (PTM double hit) of tumor suppressor protein PTEN is an important mechanism of tumorigenesis in PTEN low-frequency mutation tumor types.